Gain Therapeutics Inc., a clinical-stage biotechnology company, has announced its intention to offer shares of its common stock and warrants in an underwritten public offering, as detailed in a prospectus filed with the SEC. The company plans to use the proceeds to advance the development of its lead product candidate, GT-02287, aimed at treating neurodegenerative diseases like GBA1 Parkinson's disease. Newbridge Securities Corporation is serving as the sole book-running manager for the offering. The specific terms and timing of the offering will depend on market conditions, and a preliminary prospectus supplement will be made available through the SEC's website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。